Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the children's oncology group

Cancer

Volumn 106, Issue 8, 2006, Pages 1821-1828

  Zwerdling, Ted ^a   Krailo, Mark ^b,c   Monteleone, Philip ^d   Byrd, Rebecca ^e   Sato, Judith ^f   Dunaway, Rose ^g   Seibel, Nita ^h   Chen, Zhengjia ^c   Strain, John ⁱ   Reaman, Gregory ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ CHILDREN S HOSPITAL   (United States)

Author keywords

Docetaxel; Ewing sarcoma activity; Neutropenia; Phase II; Recurrent pediatric solid tumors

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BLEEDING; BLISTER; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; DYSPNEA; EDEMA; ERYTHEMA; EWING SARCOMA; FEMALE; GLIOMA; HUMAN; HYPOTENSION; INFANT; INFECTION; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SKIN MANIFESTATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR RECURRENCE; VISUAL IMPAIRMENT;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; SARCOMA; TAXOIDS;

EID: 33646045624     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21779     Document Type: Article

References (26)

1. Smith MA, Gloeckler Reis LA. Childhood cancer: incidence, survival and mortality. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott, Williams & Williams; 2002:1-12.
2. Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845-4852.
3. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere®): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288-291.
4. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003;3:291-306.
5. Blaney SM, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997;15:1538-1543.
6. Seibel NL, Blaney SM, O'Brien M, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999;5:733-737.
7. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458-1467.
8. Mitchell PL, Basser R, Chipman M, et al. A Phase I dose-escalation of docetaxel with granulocyte colony-stimulating factor in patients with solid tumours. Ann Oncol. 2003;14:788-794.
9. Masters GA, Brockstein BE, Mani S, et al. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003;20:7-12
10. Nistico C, Cognetti F, Frontini L, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a Phase I-II study. Oncology. 2005;68:356-363.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol. 1982;5:649-655.
12. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1988.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
14. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
15. Strissel Broeker PL, Super HG, Thirman MJ, et al. Distribution of 11q23 Breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996;87:1912-1922.
16. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003;8:413-450.
17. Kraus LA, Samuel SK, Schmid SM, Dykes DJ, Waud WR, Bissery MC. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs. 2003;21:259-268.
18. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 1999;26:3-7.
19. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992;19:646-662.
20. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res. 2000;6:2598-2603.
21. Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11:144-147.
22. Bronstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287:H963-H968.
23. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J Clin Oncol. 2002;20:2824-2831.
24. Dumez H, Louwerens M, Pawinsky A, et al. The impact of drug administration sequence and pharmacokinetic interaction in a Phase I study of the combination of docetaxel and gemcitabine in patients with advanced tumors. Anticancer Drugs. 2002;13:583-593.
25. Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol. 2001;48:95-103.
26. Engels FK, Verweij J. Docetaxel administration schedule: From fever to tears? A review of randomized studies. Eur J Cancer. 2005;41:1117-1126.